Pre-IND studies of first-generation dual-targeted, fine-tuned, immune-restoring (dfir) car-t cell therapy to achieve cures of clear cell renal cell carcinoma (ccrcc)
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2110443
- Recipient
-
Dana-Farber Cancer Institute, Inc. UEI DPMGH9MG1X67
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $267,000
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Boston, MA 02115, USA
Award details come from USAspending.gov.
About this award
The Dana-Farber Cancer Institute, Inc. was awarded a $267,000 project grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program to conduct pre-industrial studies of a first-generation dual-targeted, fine-tuned, immune-restoring chimeric antigen receptor T-cell therapy to achieve cures of clear cell renal cell carcinoma. The two-year award period runs from September 30, 2021 through September 30, 2023 and will support research activities conducted in Boston, Massachusetts aimed at developing innovative medical solutions for service members and the public through advanced biomedical research focused on transforming healthcare.
Quick answers
Who received award W81XWH2110443?
W81XWH2110443 was awarded to Dana-Farber Cancer Institute, Inc. by Medical Command (Department of the Army) on September 30, 2021.
How much is award W81XWH2110443 worth?
$267,000 has been obligated on W81XWH2110443.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award